
### [NCIT:C7506](http://purl.obolibrary.org/obo/NCIT_C7506)
**Label:** Myelodysplastic Syndrome with Excess Blasts

**Subclasses:** [NCIT:C82595](http://purl.obolibrary.org/obo/NCIT_C82595) (Myelodysplastic Syndrome with Excess Blasts and Fibrosis), [NCIT:C7168](http://purl.obolibrary.org/obo/NCIT_C7168) (Myelodysplastic Syndrome with Excess Blasts-2), [NCIT:C7167](http://purl.obolibrary.org/obo/NCIT_C7167) (Myelodysplastic Syndrome with Excess Blasts-1), 

**Class expressions from DL-Learner:**

- Thing 53.94%
- [NCIT:C37175](http://purl.obolibrary.org/obo/NCIT_C37175) (Neutrophil with Pseudo Chediak-Higashi Granules) 53.33%
- [NCIT:C37174](http://purl.obolibrary.org/obo/NCIT_C37174) (Neutrophil with Cytoplasmic Hypogranularity) 53.33%
- [NCIT:C36724](http://purl.obolibrary.org/obo/NCIT_C36724) (Neutrophil with Pseudo Pelger-Huet Nucleus) 53.33%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39114](http://purl.obolibrary.org/obo/NCIT_C39114) (IGF-1 Signaling Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39112](http://purl.obolibrary.org/obo/NCIT_C39112) (IFN Gamma Signaling Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39103](http://purl.obolibrary.org/obo/NCIT_C39103) (ERBB2 Signaling Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39102](http://purl.obolibrary.org/obo/NCIT_C39102) (Skeletal Myogenesis Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39101](http://purl.obolibrary.org/obo/NCIT_C39101) (Human Cytomegalovirus Infection Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39094](http://purl.obolibrary.org/obo/NCIT_C39094) (Inhibition of Cellular Proliferation by Gleevec Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39092](http://purl.obolibrary.org/obo/NCIT_C39092) (Growth Hormone Signaling Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39091](http://purl.obolibrary.org/obo/NCIT_C39091) (Corticosteroid Cardioprotection Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39088](http://purl.obolibrary.org/obo/NCIT_C39088) (G2/M Checkpoint Pathway))) 47.49%
- [NCIT:C37173](http://purl.obolibrary.org/obo/NCIT_C37173) (Neutrophil with Abnormal Cytoplasmic Granulation) and (not ([NCIT:C39079](http://purl.obolibrary.org/obo/NCIT_C39079) (Fc Epsilon Receptor I Signaling Pathway BioCarta))) 47.49%


